# Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

> **NCT01365468** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

## Interventions

- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT01365468
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Poor patients' accrual
- **Last updated:** 2016-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01365468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01365468, "Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01365468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*